{"entity":{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","aka":[],"tldr":"Nimbus Therapeutics is a Boston company that uses computer-aided chemistry to design pills against hard drug targets. Its cancer drug blocks an enzyme called WRN that some bowel and womb cancers with faulty DNA repair depend on.","summary":"Nimbus Therapeutics is a privately held Boston biotechnology company that designs small molecules against difficult targets using computational chemistry. Its lead oncology programme is NDI-219216, an inhibitor of the WRN helicase, which the company lists as being in a phase 1/2 trial in microsatellite instability-high (MSI-H) solid tumours; WRN dependence in MSI-H cancer is a synthetic lethal relationship. The pipeline also includes a preclinical SIK2 immunology programme and metabolic-disease collaborations with Eli Lilly. Nimbus sold its TYK2 inhibitor (now zasocitinib) to Takeda in a deal reported by STAT at 4 billion US dollars upfront, and its ACC inhibitor programme to Gilead. It raised 125 million US dollars in 2022 and 210 million US dollars in 2023 (led by GV with SR One and Atlas Venture), according to trade press coverage of the announcements.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nimbustx.com/"},{"label":"Pipeline","url":"https://www.nimbustx.com/pipeline/"},{"label":"STAT on the 2023 financing","url":"https://www.statnews.com/2023/09/06/nimbus-therapeutics-raises-210-million-in-one-of-the-larger-fundraising-rounds-this-year/"}],"tags":[],"related":["src-stat-news","src-biopharma-dive"],"cancers":[],"sections":["targeted-therapy","drug-discovery"],"technologies":["ai-drug-design","synthetic-lethality-approaches"],"targets":[],"drugs":["ndi-219216"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Nimbus's own press releases could not be located on its site (the news archive links to third-party coverage only) and no Form D filings were found under the company name. Founding year not sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.nimbustx.com/","stage":"growth","investors":["gv","sr-one","atlas-venture","sv-health-investors"],"funding":[{"round":"Crossover","year":2022,"amountUsd":125000000,"source":"https://www.biopharmadive.com/news/nimbus-venture-funding-psoriasis-tyk2/631667/","note":"Described by BioPharma Dive as a private funding round; no series letter given"},{"round":"Crossover","year":2023,"amountUsd":210000000,"source":"https://www.statnews.com/2023/09/06/nimbus-therapeutics-raises-210-million-in-one-of-the-larger-fundraising-rounds-this-year/","note":"Described by STAT as a private financing round led by GV with SR One and Atlas Venture; no series letter given"}]},"route":"/companies/nimbus-therapeutics/","neighbours":{"collection":[{"id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","route":"/collections/src-biopharma-dive/"},{"id":"src-stat-news","kind":"collection","name":"STAT News","route":"/collections/src-stat-news/"}],"section":[{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"drug":[{"id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/"}],"company":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/"},{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/"},{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/"},{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/"}],"trial":[{"id":"nct05128487","kind":"trial","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","route":"/trials/nct05128487/"},{"id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","route":"/trials/nct06898450/"}]}}